Maharashtra, India

Baviskar Pravin

This inventor holds 1 USPTO granted patent. Top assignee: Reliance Life Sciences Pvt. Ltd.. Active years: 2014.


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Baviskar Pravin: Innovator in Tetrazine Derivatives

Introduction

Baviskar Pravin is a notable inventor based in Maharashtra, India. He has made significant contributions to the field of pharmaceuticals through his innovative research and development efforts. His work primarily focuses on the preparation of tetrazine derivatives, which have important applications in medicinal chemistry.

Latest Patents

Baviskar Pravin holds a patent for a process for the preparation of tetrazine derivatives. This patent outlines a method for synthesizing a tetrazine derivative of a specific formula, which can be utilized in various pharmaceutical applications. The process involves several steps, including the absorption of a compound into a solvent, the addition of another compound to obtain the desired tetrazine derivative, and the optional salification of the compound with a pharmaceutically acceptable acid or base. He has 1 patent to his name.

Career Highlights

Baviskar Pravin is currently employed at Reliance Life Sciences Pvt. Ltd., where he continues to advance his research in pharmaceutical sciences. His work has contributed to the development of new therapeutic agents, showcasing his commitment to innovation in the field.

Collaborations

Some of his coworkers include Gupte Rajan and Chaturvedi Rohit, with whom he collaborates on various research projects. Their combined expertise enhances the research output and fosters a productive work environment.

Conclusion

Baviskar Pravin is a dedicated inventor whose work in tetrazine derivatives exemplifies the importance of innovation in pharmaceuticals. His contributions are paving the way for new advancements in medicinal chemistry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…